183 related articles for article (PubMed ID: 29393971)
1. Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model.
Fossler MJ; Sadler BM; Farrell C; Burt DA; Pitsiu M; Skobieranda F; Soergel DG
J Clin Pharmacol; 2018 Jun; 58(6):762-770. PubMed ID: 29393971
[TBL] [Abstract][Full Text] [Related]
2. Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model.
Fossler MJ; Sadler BM; Farrell C; Burt DA; Pitsiu M; Skobieranda F; Soergel DG
J Clin Pharmacol; 2018 Jun; 58(6):750-761. PubMed ID: 29412458
[TBL] [Abstract][Full Text] [Related]
3. APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Singla NK; Skobieranda F; Soergel DG; Salamea M; Burt DA; Demitrack MA; Viscusi ER
Pain Pract; 2019 Sep; 19(7):715-731. PubMed ID: 31162798
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Ayad S; Demitrack MA; Burt DA; Michalsky C; Wase L; Fossler MJ; Khanna AK
Clin Drug Investig; 2020 Aug; 40(8):755-764. PubMed ID: 32583295
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine.
Nafziger AN; Arscott KA; Cochrane K; Skobieranda F; Burt DA; Fossler MJ
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):639-650. PubMed ID: 31697049
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Characters of Oliceridine, a μ-Opioid Receptor G-Protein-Biased Ligand in Mice.
Liang DY; Li WW; Nwaneshiudu C; Irvine KA; Clark JD
Anesth Analg; 2019 Nov; 129(5):1414-1421. PubMed ID: 30044299
[TBL] [Abstract][Full Text] [Related]
7. Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain.
Tan HS; Habib AS
Expert Opin Drug Saf; 2021 Nov; 20(11):1291-1298. PubMed ID: 34370562
[TBL] [Abstract][Full Text] [Related]
8. Oliceridine: First Approval.
Markham A
Drugs; 2020 Nov; 80(16):1739-1744. PubMed ID: 33025536
[TBL] [Abstract][Full Text] [Related]
9. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
Singla N; Minkowitz HS; Soergel DG; Burt DA; Subach RA; Salamea MY; Fossler MJ; Skobieranda F
J Pain Res; 2017; 10():2413-2424. PubMed ID: 29062240
[TBL] [Abstract][Full Text] [Related]
10. Oliceridine for the Management of Acute Postoperative Pain.
Liu Y; Hu Q; Yang J
Ann Pharmacother; 2021 Oct; 55(10):1283-1289. PubMed ID: 33423508
[TBL] [Abstract][Full Text] [Related]
11. Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
Bergese S; Berkowitz R; Rider P; Ladouceur M; Griffith S; Segura Vasi A; Cochrane K; Wase L; Demitrack MA; Habib AS
Pain Res Manag; 2020; 2020():7492865. PubMed ID: 33163127
[TBL] [Abstract][Full Text] [Related]
12. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain.
Gan TJ; Wase L
Drugs Today (Barc); 2020 Apr; 56(4):269-286. PubMed ID: 32309822
[TBL] [Abstract][Full Text] [Related]
13. The Utilization of Mu-Opioid Receptor Biased Agonists: Oliceridine, an Opioid Analgesic with Reduced Adverse Effects.
Urits I; Viswanath O; Orhurhu V; Gress K; Charipova K; Kaye AD; Ngo A
Curr Pain Headache Rep; 2019 Mar; 23(5):31. PubMed ID: 30880365
[TBL] [Abstract][Full Text] [Related]
14. Oliceridine in the treatment of moderate to severe acute pain.
Eleswarpu SS; Habib AS
Pain Manag; 2021 May; 11(3):237-248. PubMed ID: 33455450
[TBL] [Abstract][Full Text] [Related]
15. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy.
Viscusi ER; Skobieranda F; Soergel DG; Cook E; Burt DA; Singla N
J Pain Res; 2019; 12():927-943. PubMed ID: 30881102
[TBL] [Abstract][Full Text] [Related]
16. Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine.
Simons P; van der Schrier R; van Lemmen M; Jansen S; Kuijpers KWK; van Velzen M; Sarton E; Nicklas T; Michalsky C; Demitrack MA; Fossler M; Olofsen E; Niesters M; Dahan A
Anesthesiology; 2023 Mar; 138(3):249-263. PubMed ID: 36538359
[TBL] [Abstract][Full Text] [Related]
17. Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics.
Pedersen MF; Wróbel TM; Märcher-Rørsted E; Pedersen DS; Møller TC; Gabriele F; Pedersen H; Matosiuk D; Foster SR; Bouvier M; Bräuner-Osborne H
Neuropharmacology; 2020 Apr; 166():107718. PubMed ID: 31351108
[TBL] [Abstract][Full Text] [Related]
18. A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain.
Viscusi ER
Expert Rev Neurother; 2022 Jun; 22(6):419-426. PubMed ID: 35502668
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain.
Simpson KN; Fossler MJ; Wase L; Demitrack MA
J Comp Eff Res; 2021 Oct; 10(15):1107-1119. PubMed ID: 34240625
[TBL] [Abstract][Full Text] [Related]
20. Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events.
Simpson KN; Fossler MJ; Wase L; Demitrack MA; Wandstrat TL
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):671-681. PubMed ID: 35129031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
